InMed Pharmaceuticals (INM) Cash from Operations Growth (1y) (2020 - 2026)
InMed Pharmaceuticals (INM) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 425.00% |
| 10 | InMed Pharmaceuticals | 6.80 Mn | 1.56 Mn | - | -2.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.15% |
| Dec 31, 2025 | 5.03% |
| Sep 30, 2025 | 12.00% |
| Jun 30, 2025 | -72.81% |
| Mar 31, 2025 | 14.21% |
| Dec 31, 2024 | -35.39% |
| Sep 30, 2024 | 15.98% |
| Jun 30, 2024 | -56.42% |
| Mar 31, 2024 | -16.76% |
| Dec 31, 2023 | 31.88% |
| Sep 30, 2023 | 3.61% |
| Jun 30, 2023 | 83.74% |
| Mar 31, 2023 | 69.03% |
| Dec 31, 2022 | 23.22% |
| Sep 30, 2022 | 15.01% |
| Jun 30, 2022 | -101.75% |
| Mar 31, 2022 | -15.99% |
| Dec 31, 2021 | -96.17% |
| Sep 30, 2021 | -93.49% |
| Jun 30, 2021 | -43.43% |